Smith & Nephew tumbles after cutting sales outlook on weak US hips and knees - UPDATE Proactive uses images sourced from ShutterstockSmith & Nephew PLC (LSE:SN) shares tumbled 6.6% to 1,118.5p after the medical technology group cut its full-year revenue growth forecast after weakness in its US orthopaedics and wound care businesses in the second quarter. The FTSE 100 now expects annual revenue growth of around 4%, down from its previous forecast of around 6%. Revenue rose 2.8% to $1.6 billion in the three months to June, though if currency benefits are excluded, underlying revenue growth was 1.6%, which the company said was lower than anticipated. Trading profit rose 8.1% to $566 million, while the trading margin improved to 18.3% from 17.7%. The company continues to target trading profit growth of around 8% and free cash flow of around $800 million.